Acute myeloid leukemia · 17 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ICE and ATRA Variant #01 | NPM1 | R 33 583 | — | — | — | — | — | — |
DAT Variant #03 | — | R 20 185 | 9d | — | — | — | — | — |
Daunorubicin monotherapy Variant #01 | — | R 19 658 | — | — | — | — | — | — |
7+5i Variant #01 | — | R 19 514 | 7d | — | — | — | — | — |
5+3i Variant #01 | — | R 17 390 | 5d | — | — | — | — | — |
Decitabine and Valproate Variant #01 | — | R 16 481 | 28d | — | — | — | — | — |
7+3i and Panobinostat Variant #01 Partial | — | R 11 606 | 19d | — | — | — | — | — |
Cytarabine, Daunorubicin, Mercaptopurine, Prednisolone Variant #01 | — | R 10 711 | — | — | — | — | — | — |
5+3d Variant #01 | — | R 10 112 | 5d | — | — | — | — | — |
Cytarabine, Daunorubicin, Vincristine Variant #02 | — | R 9 589 | — | — | — | — | — | — |
HAD Variant #01 Partial | — | R 8 001 | 7d | — | — | — | — | — |
7+3d Variant #01 | — | R 6 129 | — | — | 15.1 mo | — | — | 11 |
5+2d Variant #01 | — | R 5 983 | 5d | — | — | — | — | — |
VAMP (Amethopterin) Variant #01 | — | R 4 900 | 42d | — | — | — | — | — |
Cytarabine, Doxorubicin, Vincristine, Prednisolone Variant #01 | — | R 2 976 | — | — | — | — | — | — |
7+3i and Vorinostat N/A - secondary systemic drug | — | R 0 | 7d | — | — | — | — | — |
Cytarabine and Etoposide Partial | NPM1 | — | — | — | — | — | — | — |
17 of 17 regimens shown